The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-22-101.
Who won it before
33 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,842,522 in first-year total cost, median $241,500.
Most frequent study sections
- Special Emphasis Panel[ZTR1 RD-3 (01)]16
- Special Emphasis Panel[ZTR1 RD-7 (01)]9
- Special Emphasis Panel[ZTR1 RD-5 (01)]4
- Special Emphasis Panel[ZTR1 RD-2 (01)]3
- Special Emphasis Panel[ZTR1 RD-7 (02)]1
Most frequent institutions
- CHILDREN'S HOSP OF PHILADELPHIA4
- DUKE UNIVERSITY2
- JOHNS HOPKINS UNIVERSITY2
- UNIVERSITY OF FLORIDA2
- UNIVERSITY OF MINNESOTA2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Brain MRI to pre-symptomatically predict seizure onset for Sturge-Weber Syndrome1R21TR004265-01 | COMI, ANNE MOU, YANGMINGPINTO, ANNA LECTICIA | BOSTON CHILDREN'S HOSPITAL, MA | $271,133 | ZTR1 |
| 2022 | Functional Biomarkers for ALS1R21TR003589-01A1 | WILKINS, HEATHER M. | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $253,794 | ZTR1 |
| 2022 | Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis1R21TR003858-01A1 | GUPTA, NISHANT | UNIVERSITY OF CINCINNATI, OH | $243,000 | ZTR1 |
| 2022 | Validating absolute lymphocyte count and plasma sphingosine-1-phosphate as disease biomarkers of sphingosine phosphate lyase insufficiency syndrome in anticipation of a pyridoxine clinical trial1R21TR004262-01 | SABA, JULIE D | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $242,250 | ZTR1 |
| 2022 | A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS)1R21TR004257-01 | SPURNEY, ROBERT | DUKE UNIVERSITY, NC | $241,500 | ZTR1 |
| 2022 | Disease Severity Stratification in Multiple Sulfatase Deficiency1R21HD106348-01A1 | AHRENS-NICKLAS, REBECCA CLARE | CHILDREN'S HOSP OF PHILADELPHIA, PA | $232,535 | ZTR1 |
| 2022 | REFINING METRICS OF FOOD BEHAVIOR IN SMITH-MAGENIS SYNDROME1R21HD106345-01A1 | ELSEA, SARAH H.SISLEY, STEPHANIE RENEE | BAYLOR COLLEGE OF MEDICINE, TX | $225,420 | ZTR1 |
| 2022 | Clinical Trial Readiness - Primary Ciliary Dyskinesia (CTR-PCD)1R21TR004057-01 | ROSENFELD, MARGARET | SEATTLE CHILDREN'S HOSPITAL, WA | $212,161 | ZTR1 |
| 2022 | Cell-free DNA-Based Analysis for Diagnosis, Monitoring and Optimization of Therapy for Patients with Primary Central Nervous System Lymphomas1R21TR004059-01 | BETTEGOWDA, CHETANHOLDHOFF, MATTHIAS | JOHNS HOPKINS UNIVERSITY, MD | $204,687 | ZTR1 |
| 2021 | Targeting FOXM1 in chemo-resistant monocytic AML1R21TR003587-01 | GARTEL, ANDREI L | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $263,793 | ZTR1 |
| 2021 | PAR-18-953 (ASCOT-DMD)1R21TR004007-01A1 | THANGARAJH, MATHULA | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $256,214 | ZTR1 |
| 2021 | MRI Biomarkers of Disease Progression in Inherited Neuropathies1R21TR003312-01A1 | DORTCH, RICHARDLI, JUN | WAYNE STATE UNIVERSITY, MI | $246,172 | ZTR1 |
| 2021 | Dose Optimization of Nervonic Acid - a Potential Therapy to Alleviate Disease Progression in Adrenoleukodystrophy1R21TR003941-01 | KARTHA, REENA V | UNIVERSITY OF MINNESOTA, MN | $232,500 | ZTR1 |
| 2021 | Defining ichthyosis in Sjogren-Larsson syndrome for clinical trial preparedness1R21HD106350-01 | RIZZO, WILLIAM B. | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $223,198 | ZTR1 |
| 2021 | Clinical validation of at-home methods of sleep assessment in Rett Syndrome1R21TR003942-01 | PETERS, SARIKA U | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $214,422 | ZTR1 |
| 2021 | Biomarkers for 12-lipoxygenase inhibition as a therapeutic intervention for heparin-induced thrombocytopenia and thrombosis (HIT/T)1R21TR003185-01A1 | HOLINSTAT, MICHAEL ALLAN | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $208,600 | ZTR1 |
| 2021 | Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation1R21TR004006-01 | KIM, SARAH | UNIVERSITY OF FLORIDA, FL | $190,625 | ZTR1 |
| 2020 | Development of a reliable, valid, and sensitive outcome measure in Rett syndrome1R21HD103348-01 | NEUL, JEFFREY L | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $275,091 | ZTR1 |
| 2020 | Characterization of RASopathy Mutations Underlying Lymphatic Anomalies and Preparation for Clinical Development1R21TR003331-01 | LI, DONG | CHILDREN'S HOSP OF PHILADELPHIA, PA | $264,000 | ZTR1 |
| 2020 | Development and validation of clinical outcome assessments in LGMD2A1R21TR003184-01 | JOHNSON, NICHOLAS ELWOODSTATLAND, JEFFREY | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $254,174 | ZTR1 |
| 2020 | Magnetic resonance and ultrasound imaging as biomarkers for detection and monitoring of Parsonage-Turner Syndrome (PTS)1R21TR003033-01A1 | SNEAG, DARRYL | HOSPITAL FOR SPECIAL SURGERY, NY | $251,421 | ZTR1 |
| 2020 | Methods to Improve Clinical Trials for A-T1R21TR003534-01 | LEDERMAN, HOWARD M.LEFTON-GREIF, MAUREEN ANATALE, VALERIE | JOHNS HOPKINS UNIVERSITY, MD | $244,900 | ZTR1 |
| 2020 | Proof of concept treatment interventions in a rodent model of the rare disease bronchiolitis obliterans1R21TR003037-01A1 | PALMER, SCOTT M | DUKE UNIVERSITY, NC | $241,500 | ZTR1 |
| 2020 | Facilitating personalized medicine of monogenic stone patients by genetic characterization1R21TR003174-01 | HARRIS, PETER C.LIESKE, JOHN C | MAYO CLINIC ROCHESTER, MN | $238,500 | ZTR1 |
| 2020 | Preclinical evaluation of the efficacy and mechanism of action for an alkylated polyamine analogue diethylnorspermine in treating pheochromocytoma/paraganglioma1R21TR003044-01A1 | GHAYEE, HANS K. | UNIVERSITY OF FLORIDA, FL | $228,750 | ZTR1 |
| 2020 | Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome1R21TR003341-01 | BICKERS, DAVID RINSEY | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $202,500 | ZTR1 |
| 2020 | Clinical Trial Readiness for K channel inhibitors in Cantu Syndrome1R21HD103347-01 | GRANGE, DOROTHY KATHERINENICHOLS, COLIN G | WASHINGTON UNIVERSITY, MO | $196,875 | ZTR1 |
| 2019 | Biomarkers to enable ASO prevention trials in genetic prion disease carriers1R21TR003040-01 | ARNOLD, STEVEN E | MASSACHUSETTS GENERAL HOSPITAL, MA | $271,761 | ZTR1 |
| 2019 | Frataxin measurement for clinical trial readiness in Friedreich ataxia1R21TR003035-01 | LYNCH, DAVID ROBINSON | CHILDREN'S HOSP OF PHILADELPHIA, PA | $267,601 | ZTR1 |
| 2019 | Systemic biomarkers of brain injury from hyperammonemia1R21TR003166-01 | AH MEW, NICHOLASCALDOVIC, LJUBICA MORIZONO | CHILDREN'S RESEARCH INSTITUTE, DC | $260,407 | ZTR1 |
| 2019 | Distensibility and Remodeling as markers of Therapeutic Response in Eosinophilic Esophagitis1R21TR003039-01 | MENARD-KATCHER, CALIES DMUIR, AMANDA BROOKE | CHILDREN'S HOSP OF PHILADELPHIA, PA | $242,750 | ZTR1 |
| 2019 | Evaluating the psychometric properties of three clinical trial outcome measures for Rett syndrome1R21HD101075-01 | BYIERS, BREANNE J | UNIVERSITY OF MINNESOTA, MN | $231,288 | ZTR1 |
| 2019 | Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes1R21TR003034-01 | SHY, MICHAEL E. | UNIVERSITY OF IOWA, IA | $209,000 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.